NREP
NEW REPRESENTATIVE AT IB RECEIVED
31/01/2025
Voltar para busca
Dado oficial do USPTO
BIONTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000079349208Classe
1, 5, 9, 10, 35, 42, 44
Pedido
79349208
Registro
7129110
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
03/04/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 9, 10, 35, 42, 44
Data de depósito
28/12/2021
Data de registro
08/08/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/08/2023
Última transação
03/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
DE
Examinador
RENNEKER, CHRISTOPHER
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
B. S. (pessoa física)
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 10Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in pharmaceutical industry; active chemical ingredients for use in manufacture of anti-cancer drugs and vaccines; adjuvants for use in manufacture of vaccines; nucleic acidsproteins and peptides for laboratory use; diagnostic preparations for scientific or research use other than for medical purposes
Classe 5
Pharmaceutical products for the prevention and treatment of cancerinfectious diseasesimmunological diseasesexcept vitamin preparationsmineral food supplementsprobioticsomega 3 preparationsdietetic substances and food supplements for medical and non-medical purposes; vaccines; chemical reagents used for medical purposes; biochemical reagents used for purposes for the treatment of cancertreatment of immunological diseasestreatment of infectious diseases; macromoleculesnucleic acid sequences and proteinsused for medical and veterinary purposes; cell based immune therapeutics for treatment of cancertreatment of immunological diseasestreatment of infectious diseases; diagnostic preparations for clinical or medical laboratory use
Classe 9
Downloadable mobile applications for enabling healthcare professionals and patients to access information on pharmaceuticalmedical and vaccine products and services; downloadable computer software for enabling healthcare professionals and patients to access information on pharmaceuticalmedical and vaccine products and services; downloadable e-commerce computer software for enabling users to perform electronic business transactions via a global computer network
Classe 10
Medical diagnostic devices for analysis of body fluids and biopsies for diagnosis and monitoring of cancerinfectious diseasesimmunological diseases; medical diagnostic devices for analysis of body fluids and biopsies for patient stratification
Classe 35
Business advisory services in the field of electronic commerce; providing business information in the field of electronic commerce; providing business informationcustomer information on pharmaceutical and medical products through an on-line computer network; wholesale and retail store services featuring pharmaceutical productsmedicinal preparationsmedical supplies
Classe 42
Medical and scientific research in the field of treatment of immunological diseasescancer treatmenttreatment of infectious diseases; providing medical and scientific research informationconsultancyadvisory servicesall in the fields of medical and scientific research in the field of treatment of immunological diseasescancer treatmenttreatment of infectious diseases; medical and scientific research services by compiling data for clinical trials and drug admission
Classe 44
Medicalhygienic and beauty care; health care; providing medical information to patients and healthcare professionals concerning pharmaceutical productsvaccinesmedical productsmedical diseases and disorders and related treatments via the Internet; gene and cell therapy; medical and psychological counselling services; medical servicesproviding therapies for treating cancerinfectious diseases and immunological diseases; veterinary servicesproviding therapies for treating cancerinfectious diseasesimmunological diseases; medical and pharmaceutical consultation; medical diagnostic testingmonitoring and reporting services; genetic testing for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/12/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/11/2023
FIMP
FINAL DISPOSITION PROCESSED
13/11/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/09/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/09/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/09/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
24/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/05/2023
PUBO
PUBLISHED FOR OPPOSITION
23/05/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/04/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
18/04/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/04/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
18/04/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/03/2023
RFNT
REFUSAL PROCESSED BY IB
10/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/12/2022
RFRR
REFUSAL PROCESSED BY MPU
16/12/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/10/2022
CNRT
NON-FINAL ACTION WRITTEN
04/10/2022
DOCK
ASSIGNED TO EXAMINER
30/09/2022
MAFR
APPLICATION FILING RECEIPT MAILED
20/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/09/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
12/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIONTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.